Back to Search Start Over

Clinical Course of acute-on-chronic liver failure syndrome and effects on prognosis.

Authors :
Gustot, Thierry
Fernandez, Javier
Garcia, Elisabet
Morando, Filippo
Caraceni, Paolo
Alessandria, Carlo
Laleman, Wim
Trebicka, Jonel
Elkrief, Laure
Hopf, Corinna
Solis-Muñoz, Pablo
Saliba, Faouzi
Zeuzem, Stefan
Albillos, Augustin
Benten, Daniel
Montero-Alvarez, José Luis
Chivas, Maria Teresa
Concepción, Mar
Cordoba, Juan
McCormick, Aiden
Stauber, Rudolf
Vogel, Wolfgang
de Gottardi, Andrea
Welzel, Tania TM
Domenicali, Marco
Risso, Alessandro
Wendon, Julia
Deulofeu, Carme
Angeli, Paolo
Durand, François
Pavesi, Marco
Gerbes, Alexander L.
Jalan, Rajiv
Moreau, Richard
Ginès, Pere
Bernardi, Mauro
Arroyo, Vicente
CANONIC Study Investigators of the EASL-CLIF Consortium
Gustot, Thierry
Fernandez, Javier
Garcia, Elisabet
Morando, Filippo
Caraceni, Paolo
Alessandria, Carlo
Laleman, Wim
Trebicka, Jonel
Elkrief, Laure
Hopf, Corinna
Solis-Muñoz, Pablo
Saliba, Faouzi
Zeuzem, Stefan
Albillos, Augustin
Benten, Daniel
Montero-Alvarez, José Luis
Chivas, Maria Teresa
Concepción, Mar
Cordoba, Juan
McCormick, Aiden
Stauber, Rudolf
Vogel, Wolfgang
de Gottardi, Andrea
Welzel, Tania TM
Domenicali, Marco
Risso, Alessandro
Wendon, Julia
Deulofeu, Carme
Angeli, Paolo
Durand, François
Pavesi, Marco
Gerbes, Alexander L.
Jalan, Rajiv
Moreau, Richard
Ginès, Pere
Bernardi, Mauro
Arroyo, Vicente
CANONIC Study Investigators of the EASL-CLIF Consortium
Source :
Hepatology, 62 (1
Publication Year :
2015

Abstract

Acute-on-chronic liver failure (ACLF) is characterized by acute decompensation (AD) of cirrhosis, organ failure(s), and high 28-day mortality. We investigated whether assessments of patients at specific time points predicted their need for liver transplantation (LT) or the potential futility of their care. We assessed clinical courses of 388 patients who had ACLF at enrollment, from February through September 2011, or during early (28-day) follow-up of the prospective multicenter European Chronic Liver Failure (CLIF) ACLF in Cirrhosis study. We assessed ACLF grades at different time points to define disease resolution, improvement, worsening, or steady or fluctuating course. ACLF resolved or improved in 49.2%, had a steady or fluctuating course in 30.4%, and worsened in 20.4%. The 28-day transplant-free mortality was low-to-moderate (6%-18%) in patients with nonsevere early course (final no ACLF or ACLF-1) and high-to-very high (42%-92%) in those with severe early course (final ACLF-2 or -3) independently of initial grades. Independent predictors of course severity were CLIF Consortium ACLF score (CLIF-C ACLFs) and presence of liver failure (total bilirubin ≥12 mg/dL) at ACLF diagnosis. Eighty-one percent had their final ACLF grade at 1 week, resulting in accurate prediction of short- (28-day) and mid-term (90-day) mortality by ACLF grade at 3-7 days. Among patients that underwent early LT, 75% survived for at least 1 year. Among patients with ≥4 organ failures, or CLIF-C ACLFs >64 at days 3-7 days, and did not undergo LT, mortality was 100% by 28 days.<br />SCOPUS: ar.j<br />FLWIN<br />info:eu-repo/semantics/published

Details

Database :
OAIster
Journal :
Hepatology, 62 (1
Notes :
1 full-text file(s): application/pdf, English
Publication Type :
Electronic Resource
Accession number :
edsoai.ocn915528892
Document Type :
Electronic Resource